Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 6Adrenalin
02 1Auvi-Q
03 1Auvi-Q/Allerject
04 6EpiPen
05 2EpiPen? Auto-Injectors
06 2Epipen
07 1Epipen (a)
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : 20.00%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Cardiovascular
Currency : USD
2015 Revenue in Millions : 79
2014 Revenue in Millions : -6
Growth (%) : -108%
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 303
2018 Revenue in Millions : 303
Growth (%) : 0
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 152
2019 Revenue in Millions : 179
Growth (%) : -15
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 297
2019 Revenue in Millions : 303
Growth (%) : -2
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 125
2020 Revenue in Millions : 152
Growth (%) : -18
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 114
2021 Revenue in Millions : 125
Growth (%) : -8
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 100
2022 Revenue in Millions : 114
Growth (%) : -13
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 378
2021 Revenue in Millions : 392
Growth (%) : -3
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 442
2022 Revenue in Millions : 378
Growth (%) : 17
LOOKING FOR A SUPPLIER?